Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Asthma. 2023 Mar;60(3):625-634. doi: 10.1080/02770903.2022.2083634. Epub 2022 Jun 3.
To determine if the addition of home environmental control strategies (ECSs) to controller medication titration reduces asthma controller medication requirements and in-home allergen concentrations among children with persistent asthma in Baltimore City.
155 children ages 5-17 with allergen-sensitized asthma were enrolled in a 6-month randomized clinical trial of multifaceted, individually-tailored ECS plus asthma controller medication titration compared to controller medication titration alone. Participants had to meet criteria for persistent asthma and have had an exacerbation in the previous 18 months. Allergen sensitization (mouse, cockroach, cat, dog, dust mite) was assessed at baseline and home dust allergen concentrations were measured at baseline, 3 and 6 months. ECS was delivered 3-4 times over the trial. Asthma controller medication was titrated using a guidelines-based algorithm at baseline, 2, 4, and 6 months. The primary outcome was controller medication treatment step at 6 months (0-6, as-needed albuterol to high-dose ICS + LABA).
The population was predominately Black (90%), on public insurance (93%), and male (61%). The mean age was 10.1 years (SD 3.3). More than 70% were sensitized to a rodent, >50% to cockroach, and 70% were polysensitized. At 6 months, there were no differences in either treatment step (3.8 [SD 1.4] vs. 3.7 [SD 1.5]) or allergen concentrations between groups.
Among this predominantly low-income, Black pediatric asthma population, the addition of ECS to controller medication titration reduced neither indoor allergen concentrations nor controller medication requirements compared to controller medication titration alone.
确定在家居环境控制策略(ECS)的基础上增加控制器药物滴定是否能减少巴尔的摩市持续性哮喘儿童的哮喘控制器药物需求和室内过敏原浓度。
155 名 5-17 岁的变应原致敏哮喘儿童参加了一项为期 6 个月的随机临床试验,该试验采用多方面、个体化定制的 ECS 加哮喘控制器药物滴定与单纯控制器药物滴定进行比较。参与者必须符合持续性哮喘的标准,并且在过去 18 个月中有过一次加重。在基线时评估过敏原致敏(鼠、蟑螂、猫、狗、尘螨),并在基线、3 个月和 6 个月时测量室内灰尘过敏原浓度。在试验过程中,ECS 进行了 3-4 次。在基线、2、4 和 6 个月时,根据指南滴定哮喘控制器药物。主要结局是 6 个月时的控制器药物治疗步骤(0-6,按需沙丁胺醇至高剂量 ICS+LABA)。
该人群主要为黑人(90%),享受公共保险(93%),男性(61%)。平均年龄为 10.1 岁(SD 3.3)。超过 70%对啮齿动物过敏,超过 50%对蟑螂过敏,超过 70%对多种过敏原过敏。6 个月时,两组在治疗步骤(3.8 [SD 1.4] 与 3.7 [SD 1.5])或过敏原浓度方面均无差异。
在这个以低收入、黑人儿童为主的哮喘人群中,与单纯控制器药物滴定相比,ECS 的加入并没有降低室内过敏原浓度或控制器药物需求。